Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

65.12USD
11:33am EDT
Change (% chg)

$0.57 (+0.88%)
Prev Close
$64.55
Open
$64.73
Day's High
$65.12
Day's Low
$64.55
Volume
680,632
Avg. Vol
2,973,966
52-wk High
$66.80
52-wk Low
$55.10

Select another date:

Tue, May 23 2017

FDA clears Merck's Keytruda based on cancer genetics, not location

Merck & Co's immunotherapy Keytruda on Tuesday became the first cancer drug ever approved by the U.S. Food and Drug Administration based on a patients' specific genetic traits, regardless of where in the body the disease originated.

UPDATE 2-FDA clears Merck's Keytruda based on cancer genetics, not location

May 23 Merck & Co's immunotherapy Keytruda on Tuesday became the first cancer drug ever approved by the U.S. Food and Drug Administration based on a patients' specific genetic traits, regardless of where in the body the disease originated.

FDA clears Merck's Keytruda for cancer patients with certain biomarkers

The U.S. Food and Drug Administration on Tuesday approved Merck & Co's immuno-oncology treatment, Keytruda, for cancer patients who carry a specific genetic feature.

UK competition watchdog accuses Merck of obstructing biosimilars

LONDON Britain's competition watchdog has accused Merck & Co of operating an unfair discount scheme for its medicine Remicade that it said was designed to restrict competition from so-called biosimilar copies.

FDA clears Merck's Keytruda for cancer patients with certain biomarkers

May 23 The U.S. Food and Drug Administration on Tuesday approved Merck & Co's immuno-oncology treatment, Keytruda, for cancer patients who carry a specific genetic feature.

BRIEF-Merck sets quarterly dividend of $0.47 per share

* Sets quarterly dividend of $0.47 per share Source text for Eikon: Further company coverage:

UK competition watchdog accuses Merck of obstructing biosimilars

LONDON Britain's competition watchdog has accused Merck & Co of operating an unfair discount scheme for its medicine Remicade that it said was designed to restrict competition from so-called biosimilar copies.

UPDATE 2-UK competition watchdog accuses Merck of obstructing biosimilars

* CMA can fine companies up to 10 pct of global turnover (Adds details on past fines, more on biosimilars market)

BRIEF-FDA grants priority review to Merck's supplemental marketing application for Keytruda

* FDA grants priority review to Merck’S supplemental biologics license application (sbla) for Keytruda® (pembrolizumab) for treatment of recurrent or advanced gastric or gastroesophageal junction adenocarcinoma

UK competition watchdog accuses Merck of obstructing biosimilars

LONDON, May 23 Britain's competition watchdog on Tuesday accused Merck & Co of operating an anti-competitive discount scheme for its medicine Remicade, designed to restrict competition from so-called biosimilar copies of the drug.

Select another date:

More From Around the Web